EGFR and non-small cell lung carcinoma: They reported that the OS of PD-L1 positive EGFRm NSCLC patients was worse than that of PD-L1 negative patients (median OS 15.2 vs 29.3 months, p = 0.006), although most of these patients also received EGFR TKI monotherapy in all treatment lines.